R 1 is hydrogen or fluorine; R 2 is methyl or ethyl; R, is hydroxy, C 1 -C 4 alkanoyloxy, aminocarbonyl. methylaminocarbonyl or C 1 -C 2 alkoxycarbonyl; C is an asymmetric carbon atom having the R absolute stereochemical configuration; and C is an asymmetric carbon atom having the S absolute stereochemical configuration;
and pharmaceutically-acceptable salts thereof, are useful in the weight control of mammals.
摘要:
Novel rexinoid compounds are provided herein. Also provided herein are methods of using the compounds to treat disorders, such as metabolic disorders, diabetes, insulin resistance, glucose intolerance, obesity, steatosis, inflammation, and/or cancer.
摘要:
The present invention relates to the technical field of organic chemistry, specifically an asymmetrical hydrogenation of an α-ketonic acid compound, the technical proposal being as shown by the following formula:
Wherein R 1 is a phenyl, a substituted phenyl, a naphthyl, a substituted naphthyl, a C 1 -C 6 alkyl or aralkyl, the substitute is a C 1 -C 6 alkyl, a C 1 -C 6 alkoxy, a halogen, the number of the substituents is 1-3. M is a chiral spiro-pyridyl amido phosphine ligand iridium complex having the following structure,
Wherein, R is hydrogen, 3-methyl, 4- t Bu or 6-methyl.
摘要:
Disclosed is a new method for preparing an azetidinone compound represented by formula (I). The carboxylic ketoester represented by formula (II) serves as the raw material and is subjected to Grignard addition, stereoselective dehydration, ester group reduction, hydroxyl group protection, addition with imine after condensation with a chiral auxiliary, cyclization and deprotection to obtain the compound represented by formula (I). The present invention has advantages of easily available raw material, a few synthetic steps, simple operation, high yield, good stereoselectivity and low cost, and can be used for industrial production.
摘要:
The present invention provides an alternative synthesis of N-substituted aminotetralines comprising resolution of N-substituted aminotetralins of formula (II), wherein R 1 , R 2 and R 3 are as defined for compound of formula (I).
摘要:
The present invention relates to compounds having the general formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, R10 given below, and solvates, hydrates, esters, and pharmaceutically acceptable salts thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of γ-secretase activity.
摘要:
There is provided a novel loxoprofen derivative that has no side effect such as a gastrointestinal disorder and also has excellent anti-inflammatory and analgesic effects and is represented by the following formula (I) or (II):
(wherein R 1 and R 2 each represent a halogen atom or a substituted or unsubstituted phenyl group) or a pharmacologically acceptable salt thereof. In the derivative, the halogen atom is selected from a chlorine atom, a bromine atom, a fluorine atom, and an iodine atom, and a substituent of the substituted phenyl group is a halogen atom, a hydroxyl group, a substituted or unsubstituted lower alkyl group, a lower alkylthio group, a lower alkoxy group, a nitro group, an amino group, or a carboxyl group.